SC-57461A is an orally bioactive, non-peptide, selective leukotriene A4 (LTA4) hydrolase inhibitor (antagonist) with IC50s of 2.5 nM, 3 nM and 3 nM for recombinant human, mouse and mouse LTA4 hydrolase, respectively. 23 nM.

Physicochemical Properties

Molecular Formula	C20H25NO3
Molecular Weight	327.42
Exact Mass	363.16
CAS #	423169-68-0
PubChem CID	9820433
Appearance	White to off-white solid powder
Density	1.115g/cm3
Boiling Point	499.7ºC at 760 mmHg
Flash Point	256.01ºC
Index of Refraction	1.562
LogP	4.254
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	10
Heavy Atom Count	25
Complexity	347
Defined Atom Stereocenter Count	0
Synonyms	SC57461; SC-57461; SC 57461
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	In whole blood, SC-57461A suppresses the synthesis of LTB4 induced by ionophores with IC50 values of 49, 166, and 466 nM for human, mouse, and topovirus, respectively [1]. The LTA4 fine-tuned enzyme (IC50=2.5 nM) and entire cells (IC50=49 nM) are both effectively inhibited by SC-57461A [2].
ln Vivo	SC-57461A also showed excellent effects in in vitro mouse experiments, inhibiting the production of LTB4 with ED50=0.2 mg/kg and ED90=1 mg/kg. SC-57461A also inhibits LTB4 production in the peritoneal model with ED50=1 mg/kg[2]. SC-57461A is a potent, selective, competitive inhibitor of the LTA4 disinfecting enzyme with excellent activity in whole animals. SC-57461A in mice and mice
Animal Protocol	Animal/Disease Models: Fasted CD rat [3] Doses: 0.01, 0.1, 1 and 10 mg/kg Route of Administration: Oral Experimental Results: ED50 value at 1.0 is 0.2 mg/kg . h and 0.8 mg/kg at 3.0 h. A single dose of 10 mg/kg prevented 79%, 67% and 44% of LTB4 production at 6 hrs (hrs (hours)), 18 hrs (hrs (hours)) and 24 hrs (hrs (hours)), respectively.
References	[1]. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies. J Pharmacol Exp Ther. 2002 Feb;300(2):577-82. [2]. T D Penning. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents. Curr Pharm Des. 2001 Feb;7(3):163-79. [3]. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. J Pharmacol Exp Ther. 2002 Feb;300(2):583-7.

Solubility Data

Solubility (In Vitro)

DMSO : ~250 mg/mL (~687.04 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (5.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (5.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.0542 mL	15.2709 mL	30.5418 mL
	5 mM	0.6108 mL	3.0542 mL	6.1084 mL
	10 mM	0.3054 mL	1.5271 mL	3.0542 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.